新结果表明ACTOS. (pioglitazone HCl) 显著地减少了2 型糖尿病人致命与非致命心脏病和急性冠状综合症的再发生。重要的是这些结果优于已知的治疗标准。研究结果今天发表在美国心脏协会的2005 年科学会议上。它是基于早先报告的前瞻研究结果之上。结果显示ACTOS, 一种口头抗糖尿疗程, 极大减少了2 型糖尿高风险病人心脏病发作, 中风和死亡综合风险的百分之16。

New Data Shows Eli Lilly and Company (LLY)'s ACTOS? (pioglitazone HCl) Reduced Heart Attacks By 28 Percent In People With Type 2 Diabetes

New results from secondary analyses of the landmark PROactive Study found that ACTOS? (pioglitazone HCl) significantly reduced the occurrence of fatal and non-fatal heart attacks and acute coronary syndrome (ACS) in high-risk patients with type 2 diabetes who had a previous heart attack. Importantly, these results were above and beyond those seen with standard of care treatment. The findings, which were revealed today at the American Heart Association's Scientific Sessions 2005, build on previously-reported results from the PROactive Study, showing that ACTOS, an oral antidiabetic medication, significantly reduced the combined risk of heart attacks, strokes and death by 16 percent in high-risk patients with type 2 diabetes.